SCHEMBL1001273

SCHEMBL1001273

CCCCOc1cc(NC(=O)c2cccc(S(=O)(=O)c3ccccn3)c2)[nH]n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 1/20 0.42
KDM4A O75164 2/20 0.41
KDM4B O94953 2/20 0.41
KDM5B Q9UGL1 2/20 0.41
THRB P10828 1/20 0.40
TSHR P16473 3/20 0.39
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
LMNA P02545 3/20 0.39
ALDH1A1 P00352 2/20 0.39
BCL2L1 Q07817 1/20 0.39
MCL1 Q07820 1/20 0.39
GAA P10253 1/20 0.38
KDM5C P41229 1/20 0.38
KMT2A Q03164 4/20 0.38
MEN1 O00255 2/20 0.38
NR1H4 Q96RI1 1/20 0.38
KDM4E B2RXH2 1/20 0.37
PKM P14618 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1001453 0.95 KDM4A (0.42) KAT6AKDM4AKDM4BKDM5BTSHR
SCHEMBL1001241 0.92 LMNA (0.43) KAT6AKDM4AKDM4BKDM5BTSHR
SCHEMBL1000488 0.86 LMNA (0.43) KAT6AKDM4AKDM4BKDM5BTSHR
SCHEMBL1001483 0.71 SLC40A1 (0.54) TSHRHTTLMNAALDH1A1GAA
SCHEMBL1000940 0.71 RAB9A (0.48) TSHRHTTL3MBTL1LMNAALDH1A1
SCHEMBL999897 0.70 TSHR (0.45) KDM4AKDM4BKDM5BTSHRHTT
SCHEMBL1002215 0.70 SMN1; SMN2 (0.54) TSHRHTTL3MBTL1LMNAALDH1A1
SCHEMBL1001546 0.69 TSHR (0.49) KAT6ATSHRHTTL3MBTL1LMNA
SCHEMBL1002283 0.69 RAB9A (0.44) KDM4AKDM4BKDM5BTSHRHTT
SCHEMBL1000780 0.69 RAB9A (0.54) KAT6ATSHRHTTL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280001-B1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD KK (JP) 2014-10-15 EP claimed
US-8420823-B2 Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient MSD K.K. (JP) 2013-04-16 US claimed
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD K.K. (JP) 2011-01-13 US claimed
EP-2280001-B1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD KK (JP) 2014-10-15 EP disclosed
US-8420823-B2 Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient MSD K.K. (JP) 2013-04-16 US disclosed
EP-2280001-A1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT Banyu Pharmaceutical Co., Ltd. (JP) 2011-02-02 EP disclosed
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD K.K. (JP) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT ELOVL1, ELOVL6, ELOVL3 KAT6A 775/4885KDM4A 1267/4885KDM4B 2642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.